Skip to main content
Premium Trial:

Request an Annual Quote

Piper Jaffray Initiates Coverage of Trovagene with an Overweight Rating

NEW YORK (GenomeWeb) – Piper Jaffray today initiated coverage of molecular cancer diagnostic firm Trovagene with an Overweight rating and a $6.25 price target. 

Piper Jaffray analyst William Quirk estimated Trovagene revenues for full-year 2015 at $900,000 with a loss per share of $.92. In a research report, he said that while the company has successfully launched into the qualitative space, with tests for detecting BRAF, V600E, and KRAS, and plans to launch a test for EGFR T790M in Q1 2015, larger opportunities await Trovagene with expected launches this year and in 2016 into single and panel mutation monitoring. Those markets represent a $1 billion opportunity initially and $4.3 billion longer-term, Quirk said. 

"Initial quantitative data is encouraging, with mutations found in urine correlating to treatment response," he said. "We believe Trovagene's value proposition centers around the 2015 release of quantitative [cell-free DNA] tests, as well as the late 2015/2016 launch of panels designed specifically for melanoma, colorectal, pancreatic, NSCLC, and breast cancer mutational load monitoring." 

Quirk also noted a deal struck by Trovagene with Illumina in 2013 to evaluate Trovagene's technology and said that if the collaboration leads to a commercial product, his estimates for the firm "may be too low." 

Last week, San Diego-based Trovagene announced it raised $23 million in a public offering of its common stock.

In morning trading Tuesday on the Nasdaq, shares of Trovagene increased 3 percent to $5.15.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.